Charles Sabine will be a featured speaker during the upcoming 7th Annual Huntington Study Group Symposium and Workshops in Charlotte, November 7-9. Patients, families, caregivers, researchers and medical professionals are invited to learn about the Sabine family battle with Huntington’s disease and Charles’ mission to build a global community dedicated to finding better treatment and care for HD patients.
In his 26 years as a correspondent for NBC News covering wars, disasters, atrocities and other human suffering, Charles Sabine often put himself in harm’s way.
But the risks he sometimes felt on the job paled in comparison to the fear he experienced in 2004, when he was tested for and found to have Huntington’s disease, or HD.
Sometimes described as “the world’s cruellest disease,” HD causes the progressive loss of control of movement, thought and emotion, and typically results in death 15 to 25 years after onset of motor signs of the disease.
“What makes HD crueller than any other disease is that not just does it affect every aspect of a personality, rendering the victim unrecognizable to their family, but its unique genetic nature means that those family members are watching this often in the knowledge that they are going to suffer the same fate,” says Sabine, whose father died of the disease, and whose brother already is showing its physical symptoms.
Now 53 and the father of two young children, the British native and resident has made it his mission in life to connect physicians, scientists, patients, families, politicians and anyone else who is affected by or cares about HD, and in the process build a global community dedicated to finding better treatment and care of HD patients.
Because anyone who carries the disease form of the HD gene is certain to get the disease, differentiating it from all other diseases, HD is the focus of pioneering work that will have enormous impact for many diseases on issues ranging from research and treatment to care and patients rights.
HD is “a disease of the future,” he says. “It can be researched as no other disease because you can study people before they get symptoms,” he says. “And it is a vanguard for so many constitutional issues of the future that are being faced now by HD sufferers, such as who should know you have the disease, who should have information and be privy to it, whether government, or life insurers or employers.”
Sabine will be a featured speaker during the upcoming 7th Annual Huntington Study Group Clinical Research Symposium and Workshops in Charlotte. The symposium, workshops, educational and training programs will be held November 7-9 at the Omni Hotel.
Patients, families, caregivers, researchers and medical professionals are encouraged to attend.
This international gathering is jointly sponsored by Charlotte AHEC and the Huntington Study Group, or HSG, an international network of clinical researchers who study and care for patients and families with HD.
Reports on the latest clinical research on HD, now conducted at over 105 credentialed research sites in the U.S., Canada, Australia, New Zealand, Europe and South America, will be featured.
Workshops include networking for regional doctors and health care providers, continuing education for medical professionals, and training programs for service providers, caregivers and local practitioners.
Sessions will examine the issues of local social and medical care that affect the caregivers who treat HD patients and families, including the work of groups such as HD Reach, a North Carolina-based nonprofit that has pioneered efforts to make sure patients and families throughout the state, particularly in rural areas, have access to HD care and resources.
While HD affects only about 30,000 people in the U.S., an estimate first cited 20 years ago, initial findings from new research in Canada and England show the disease is twice as prevalent as previously thought, Sabine says.
His own uncle died of HD in 1992 in a care home for people with the disease, says Sabine, who did not even know of his uncle’s existence until after his death.
And because HD is age-related, he says, the number of people with the disease is surging with the graying of the population.
What’s more, he says, “huge swaths of the population have the disease but just don’t know about it, or have been misdiagnosed, or have had it hidden away.”
Now, however, a worldwide grassroots HD community has emerged in the wake of a “perfect storm” of factors, he says.
Since the HD gene was discovered in 1983, and a test for HD was developed in 1993, that community has grown through greater awareness about the disease, through the emergence of the Internet and social networking, and through the support of prominent people such as the family of folk singer Woody Guthrie, who had HD and died in 1967.
“The more that families can get involved, the quicker we will have significant treatment of the disease,” Sabine says. “Without them, research cannot move forward.”
Research offers a “crucial beacon of light to families suffering from the disease,” he says. “It’s looking increasingly promising in the next few years that there could be successful clinical trials at slowing the progression of the disease.”
The possibility of developing a treatment to slow progression of the disease “is extraordinarily empowering,” Sabine says. “Without it, it would be impossible for people to deal with the disease.”